Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionTruist Financial Corp
Latest Disclosed Ownership114,449 shares
Latest Disclosed Value $ 51,105,903
Truist Financial Corp reports 9.31% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On April 27, 2026 - Truist Financial Corp filed a 13F-HR form disclosing ownership of 114,449 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $51,106,056 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 2, 2026 disclosing 126,193 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -9.31% during the quarter. The current value of the position is $49,023,085 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-27 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 114,449 -11,744 -9.31 51,106 -10.67 0.0689
2026-02-02 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 126,193 -17,671 -12.28 57,211 1.54 0.0763
2025-11-03 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 143,864 -66,225 -31.52 56,343 -39.76 0.0762
2025-07-18 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 210,089 -13,881 -6.20 93,532 -13.86 0.1369
2025-04-29 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 223,970 12,166 5.74 108,585 27.31 0.1737
2025-01-31 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 211,804 1,885 0.90 85,293 -12.63 0.1335
2024-11-13 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 209,919 -8,722 -3.99 97,629 -4.74 0.1530
2024-08-21 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 218,641 -4,470 -2.00 102,481 9.89 0.1559
2024-05-13 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 223,111 -2,245 -1.00 93,263 1.71 0.1412
2024-02-02 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 225,356 -1,707 -0.75 91,695 16.13 0.1458
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 227,063 58,219 34.48 78,959 32.89 0.1319
2023-08-01 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 168,844 8,141 5.07 59,418 17.35 0.0988
2023-05-05 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 160,703 -10,741 -6.27 50,633 2.27 0.0871
2023-02-17 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 171,444 62,866 57.90 49,510 57.48 0.0871
2022-10-26 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 108,578 1,741 1.63 31,438 4.43 0.0603
2022-07-22 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 106,837 -4,137 -3.73 30,105 3.95 0.0553
2022-04-22 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 110,974 26,836 31.90 28,961 56.74 0.0457
2022-02-14 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 84,138 2,887 3.55 18,477 25.37 0.0282
2021-11-05 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 81,251 43,511 115.29 14,738 93.69 0.0242
2021-08-16 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 37,740 85 0.23 7,609 -5.97 0.0124
2021-05-17 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 37,655 -1,866 -4.72 8,092 -13.36 0.0141
2021-11-19 2020-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 39,521 -2,794 -6.60 9,340 -18.88 0.0179
2021-02-18 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 39,521 -2,794 9,340 0.0173
2021-11-05 2020-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 42,315 2,825 7.15 11,514 0.44 0.0252
2020-11-13 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 42,230 2,794 11,491 0.0248
2021-11-16 2020-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 39,490 4,584 13.13 11,464 38.02 0.0258
2020-08-14 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 39,436 4,530 11,448 0.0254
2021-11-05 2020-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 34,906 -265 -0.75 8,306 7.86 0.0219
2020-05-15 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 34,852 -245 8,293 0.0216
2021-11-16 2019-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 35,171 25,577 266.59 7,701 373.91 0.0156
2020-02-14 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 35,097 25,503 7,685 0.0155
2019-10-31 2019-09-30 13F VERTEX COMMON STOCK 92532F100 9,594 83 0.87 1,625 -6.88 0.0279
2019-07-24 2019-06-30 13F VERTEX COMMON STOCK 92532F100 9,511 -172 -1.78 1,745 -2.02 0.0302
2019-04-23 2019-03-31 13F VERTEX COMMON STOCK 92532F100 9,683 -94 -0.96 1,781 9.94 0.0318
2019-01-22 2018-12-31 13F VERTEX COMMON STOCK 92532F100 9,777 -685 -6.55 1,620 -19.68 0.0332
2018-10-17 2018-09-30 13F VERTEX COMMON STOCK 92532F100 10,462 104 1.00 2,017 14.60 0.0363
2018-07-26 2018-06-30 13F VERTEX COMMON STOCK 92532F100 10,358 -1,067 -9.34 1,760 -5.53 0.0335
2018-04-20 2018-03-31 13F VERTEX COMMON STOCK 92532F100 11,425 227 2.03 1,863 10.96 0.0355
2018-01-29 2017-12-31 13F VERTEX COMMON STOCK 92532F100 11,198 92 0.83 1,679 -0.59 0.0314
2017-10-23 2017-09-30 13F VERTEX COMMON STOCK 92532F100 11,106 -203 -1.80 1,689 15.92 0.0328
2017-07-20 2017-06-30 13F VERTEX COMMON STOCK 92532F100 11,309 -2,020 -15.15 1,457 0.00 0.0289
2017-04-28 2017-03-31 13F VERTEX COMMON STOCK 92532F100 13,329 5,223 64.43 1,457 144.05 0.0293
2017-02-02 2016-12-31 13F VERTEX COMMON STOCK 92532F100 8,106 45 0.56 597 -15.08 0.0122
2016-11-01 2016-09-30 13F VERTEX COMMON STOCK 92532F100 8,061 -340 -4.05 703 -2.77 0.0144
2016-08-01 2016-06-30 13F VERTEX COMMON STOCK 92532F100 8,401 308 3.81 723 12.27 0.0152
2016-05-05 2016-03-31 13F VERTEX COMMON STOCK 92532F100 8,093 67 0.83 644 -36.24 0.0167
2016-01-28 2015-12-31 13F VERTEX COMMON STOCK 92532F100 8,026 4,566 131.97 1,010 180.56 0.0262
2015-11-04 2015-09-30 13F VERTEX COMMON STOCK 92532F100 3,460 1,164 50.70 360 26.76 0.0094
2015-07-29 2015-06-30 13F VERTEX COMMON STOCK 92532F100 2,296 -45 -1.92 284 2.90 0.0077
2015-04-23 2015-03-31 13F VERTEX COMMON STOCK 92532F100 2,341 -1,725 -42.42 276 -42.86 0.0079
2015-01-26 2014-12-31 13F VERTEX COMMON STOCK 92532F100 4,066 -272 -6.27 483 -0.82 0.0142
2014-10-21 2014-09-30 13F VERTEX COMMON STOCK 92532F100 4,338 -214 -4.70 487 12.99 0.0147
2014-07-21 2014-06-30 13F VERTEX COMMON STOCK 92532F100 4,552 -515 -10.16 431 20.39 0.0129
2014-04-28 2014-03-31 13F VERTEX COMMON STOCK 92532F100 5,067 290 6.07 358 0.85 0.0113
2014-01-27 2013-12-31 13F VERTEX COMMON STOCK 92532F100 4,777 -713 -12.99 355 -14.66 0.0114
2013-10-22 2013-09-30 13F VERTEX COMMON STOCK 92532F100 5,490 181 3.41 416 -2.12 0.0147
2013-07-15 2013-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 5,309 5,309 425 0.0158
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.